Nuvalent Inc.
Nuvalent Announces Pricing for Upsized Public Offering of Common Stock
Summary
Nuvalent, Inc. announced the pricing of an upsized underwritten public offering of 5,000,000 shares of Class A common stock at $100.00 per share. All shares are being offered by Nuvalent, with the offering expected to close on September 18, 2024. The underwriters have a 30-day option to purchase up to an additional 750,000 shares. The offering is expected to generate approximately $469.5 million in net proceeds for the company, subject to customary closing conditions. The shares are being offered pursuant to an automatically effective shelf registration statement filed with the SEC.
Profitelligence Alerts
Get alerts for NUVL
Be first to know when Nuvalent Inc. files with the SEC.
Filing Categories
Exhibits (3)
Advertisement
About Nuvalent Inc.
Nuvalent Inc. is a biopharmaceutical company dedicated to the innovative development of small molecule therapies for cancer treatment. The company's primary focus is on creating targeted solutions for patients with cancer-related resistance mutations and treatment-related adverse effects. By leveraging their expertise in medicinal chemistry and deep understanding of tumor biology, Nuvalent aims to address significant gaps in current cancer therapies, particularly where existing treatments fall short due to resistance mechanisms. The company operates in a highly specialized sector that covers oncology research and development, presenting potential game-changing approaches within the broader pharmaceutical industry. Through its commitment to research and innovation, Nuvalent collaborates with leading research institutions to push the boundaries of what is achievable in cancer treatment. Situated within an ever-evolving market, the company plays a critical role in advancing new oncological solutions that may ultimately improve the quality of life for patients globally. Founded with the mission to transform patient care, Nuvalent's asset offerings are a testament to the progressive strides being made in next-generation cancer therapeutics.
Official SEC Documents
Advertisement